FLI1 and systemic lupus erythematosus: Importantly, our studies suggest that reducing FLI1 levels and/or inhibiting the glycosphingolipid metabolic pathway, may serve as a therapeutic approach for reducing lupus T cell pathogenesis and treating disease.